Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Keros Therapeutics, Inc. (KROS)

28.56   1.79 (6.69%) 06-26 21:51
Open: 27.13 Pre. Close: 26.77
High: 28.64 Low: 26.7
Volume: 548,227 Market Cap: 686(M)
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 28.68 - 28.78 28.78 - 28.87
Low: 26.43 - 26.55 26.55 - 26.66
Close: 28.36 - 28.57 28.57 - 28.73

Technical analysis

as of: 2022-06-24 4:41:15 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 38.13     One year: 44.1
Support: Support1: 24.37    Support2: 20.28
Resistance: Resistance1: 32.65    Resistance2: 37.76
Pivot: 28.86
Moving Average: MA(5): 27.39     MA(20): 30.16
MA(100): 47.55     MA(250): 45.37
MACD: MACD(12,26): -3.7     Signal(9): -4.2
Stochastic oscillator: %K(14,3): 19.6     %D(3): 12.3
RSI: RSI(14): 36
52-week: High: 68.29  Low: 24.37
Average Vol(K): 3-Month: 216 (K)  10-Days: 364 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ KROS ] has closed above bottom band by 46.1%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 24 Jun 2022
Redd Kross’ ‘Neurotica,’ a Lost ’80s Power-Pop Classic, Finally Gets Its Due: Album Review - Variety

Fri, 24 Jun 2022
Killer Kross Explains How Infamous Adam Cole Promo Came About - Wrestling Inc.

Thu, 23 Jun 2022
Opponents for NZO and Killer Kross announced for MLW Battle Riot - Cageside Seats

Wed, 22 Jun 2022
Where Will Keros Therapeutics Inc (KROS) Stock Go Next After It Has Gained 0.55% in a Week? - InvestorsObserver

Wed, 22 Jun 2022
Killer Kross vs Matt Cross signed for NYC this Thursday - MLW

Mon, 20 Jun 2022
Remembering Ruffhouse Records, the '90s Philly music label behind hits like Cypress Hill, The Fugees, and 'Jump' - Billy Penn

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 23 (M)
Shares Float 14 (M)
% Held by Insiders 11.3 (%)
% Held by Institutions 87.3 (%)
Shares Short 880 (K)
Shares Short P.Month 959 (K)

Stock Financials

EPS -2.69
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.34
Profit Margin (%) -292.3
Operating Margin (%) -280.5
Return on Assets (ttm) -13.5
Return on Equity (ttm) -23.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) -1.5
Sales Per Share 0.85
EBITDA (p.s.) -2.4
Qtrly Earnings Growth 0
Operating Cash Flow -62 (M)
Levered Free Cash Flow -39 (M)

Stock Valuations

PE Ratio -10.66
PEG Ratio 0
Price to Book value 3.05
Price to Sales 33.24
Price to Cash Flow -10.76

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.